Development and Validation of a Reverse-Phase High-Performance Liquid Chromatography with Fluorescence Detection (RP-HPLC-FL) Method to Quantify Ruxolitinib in Plasma Samples
Sign Up to like & getrecommendations! Published in 2019 at "Analytical Letters"
DOI: 10.1080/00032719.2018.1537283
Abstract: Abstract Ruxolitinib is a JAK 1/2 inhibitor approved in 2011 by the Food and Drug Administration (FDA) for the treatment of patients with myelofibrosis. Currently, side effects related to the use of ruxolitinib are routinely… read more here.
Keywords: phase; development validation; plasma; phase high ... See more keywords